Hamps Bio

Why is Hamps Bio Limited falling/rising?

As of 02-Sep, Hamps Bio Limited's stock price is stable at Rs 25.90, with a notable performance today, outperforming its sector by 6.36%. The stock is trading above key moving averages, indicating a bullish trend, and has seen increased investor participation.

As of 02-Sep, Hamps Bio Limited's stock price is currently stable at Rs 25.90, showing no change from the previous day. However, the stock has demonstrated a notable performance today, outperforming its sector by 6.36%. It opened with a significant gain of 6.12% and reached an intraday high of Rs 25.99. This positive movement can be attributed to several factors: the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bullish trend. Additionally, there has been a rise in investor participation, with delivery volume increasing by 11.11% compared to the 5-day average. Despite some erratic trading, where the stock did not trade on 4 out of the last 20 days, the overall indicators suggest a positive sentiment around Hamps Bio Limited, contributing to its rising price today.

Which are the latest news on Hamps Bio?

Who are the peers of the Hamps Bio?

Hamps Bio's peers include Pearl Green Club, TGIF Agribusines, Sunil Agro Foods, Prospect Consum., Vikas Wsp, Natura Hue Chem, Annvrridhhi Ven, and Nirman Agri. Hamps Bio has below average management risk, growth, and capital structure compared to its peers, with a 1-year return of -9.93%.

Peers: The peers of Hamps Bio are Pearl Green Club, TGIF Agribusines, Sunil Agro Foods, Prospect Consum., Vikas Wsp, Natura Hue Chem, Annvrridhhi Ven, and Nirman Agri.<BR><BR>Quality Snapshot: Excellent management risk is observed at Nirman Agri, while Average management risk is found at TGIF Agribusines, Sunil Agro Foods, and Prospect Consum., and the rest. Below Average management risk is seen at Pearl Green Club, Vikas Wsp, Hamps Bio, Annvrridhhi Ven. For growth, Excellent growth is noted at TGIF Agribusines and Prospect Consum., Average growth is found at Annvrridhhi Ven, while Below Average growth is observed at Pearl Green Club, Sunil Agro Foods, Vikas Wsp, and Hamps Bio. In terms of Capital Structure, Good capital structure is present at Pearl Green Club, TGIF Agribusines, and Prospect Consum., while Below Average capital structure is seen at Sunil Agro Foods, Vikas Wsp, Hamps Bio, and Annvrridhhi Ven.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Natura Hue Chem at 330.58%, while the lowest is Prospect Consum. at -63.92%. Hamps Bio's 1-year return is -9.93%, which is higher than Prospect Consum. but lower than Natura Hue Chem. Additionally, Vikas Wsp and Prospect Consum. have negative six-month returns.

How big is Hamps Bio?

Summary could not be generated.

As of 31st August, Hamps Bio Limited has a market capitalization of 19.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent quarterly performance data is unavailable, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>In the balance sheet snapshot for the reporting period of March 2026, Shareholder's Funds are valued at 8.10 Cr, and Total Assets amount to 15.87 Cr.

What does Hamps Bio do?

Hamps Bio Limited is a Micro Cap company in the Other Agricultural Products industry, incorporated in 2007 and publicly listed as of 2023. It currently has no available revenue or profit data, with a market cap of INR 21 Cr and a negative return on equity of -91.23%.

Overview:<BR>Hamps Bio Limited operates in the Other Agricultural Products industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Hamps Bio Limited was originally incorporated as "Hamps Bio Private Limited" in 2007. The company later changed its status to Public Limited and adopted the name "Hamps Bio Limited." The latest Certificate of Incorporation was issued on July 12, 2023. Revenue and profit data are not available for any specific quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 21 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: N/A<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.83<BR>Return on Equity: -91.23%<BR>Price-to-Book: 2.61<BR><BR>Contact Details:<BR>Registrar Address: Not available.

When is the next results date for Hamps Bio Limited?

The next results date for Hamps Bio Limited is 29 May 2026.

The next results date for Hamps Bio Limited is scheduled for 29 May 2026.

How has been the historical performance of Hamps Bio?

Hamps Bio has experienced steady revenue growth, with net sales increasing from 5.58 Cr in Mar'23 to 6.67 Cr in Mar'25, but profitability has declined, with profit after tax dropping from 0.50 Cr in Mar'24 to 0.30 Cr in Mar'25. Despite fluctuations in operating profit and rising costs, the company's equity capital and book value per share have improved, indicating a stronger financial position.

Answer:<BR>The historical performance of Hamps Bio shows a mixed trend in its financial metrics over the past three years.<BR><BR>Breakdown:<BR>Hamps Bio's net sales have increased from 5.58 Cr in Mar'23 to 6.67 Cr in Mar'25, indicating a steady growth in revenue. However, the total operating income has also risen in tandem, reflecting consistent performance. The raw material costs have surged to 0.85 Cr in Mar'25 from 0.21 Cr in Mar'23, while the purchase of finished goods decreased slightly to 2.01 Cr in Mar'25 from 2.17 Cr in Mar'24. Employee costs have risen, contributing to an overall increase in total expenditure, which reached 5.90 Cr in Mar'25 compared to 4.71 Cr in Mar'23. Operating profit (PBDIT) has shown fluctuations, peaking at 1.21 Cr in Mar'24 but dropping to 0.92 Cr in Mar'25. Profit before tax has also decreased from 0.65 Cr in Mar'24 to 0.40 Cr in Mar'25, leading to a profit after tax of 0.30 Cr in Mar'25, down from 0.50 Cr in Mar'24. The company's equity capital has significantly increased to 4.36 Cr in Mar'25 from 1.50 Cr in Mar'23, while total liabilities have risen to 12.67 Cr in Mar'25 from 3.61 Cr in Mar'22. The book value per share has improved to 20.2 in Mar'25 from 4.1875 in Mar'22, indicating a strengthening financial position despite the recent declines in profitability.

Is Hamps Bio overvalued or undervalued?

As of September 9, 2025, Hamps Bio is considered very expensive and overvalued with a PE ratio of 13.07 and an EV to EBITDA of 15.94, significantly lagging behind peers like Sun Pharma and Cipla, while also experiencing a year-to-date return of -27.42% compared to the Sensex's 3.79% gain.

As of 9 September 2025, Hamps Bio's valuation grade has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued based on its financial ratios. The PE ratio stands at 13.07, while the EV to EBITDA ratio is 15.94, and the ROE is a mere 3.41%. <BR><BR>In comparison to its peers, Hamps Bio's valuation metrics are notably less favorable; for instance, Sun Pharma has a PE ratio of 33.36 and an EV to EBITDA of 22.55, while Cipla, rated as attractive, has a PE of 23.28 and an EV to EBITDA of 16.4. This stark contrast highlights Hamps Bio's overvaluation in the current market context. Additionally, the company's recent stock performance has been underwhelming, with a year-to-date return of -27.42%, contrasting sharply with the Sensex's 3.79% gain.

What is the bonus history of Hamps Bio?

Hamps Bio recently announced a 1:1 bonus issue, granting shareholders an additional share for each share held, with an ex-date and record date of September 8, 2025.

Hamps Bio has a recent bonus issue where they announced a 1:1 bonus. This means that for every share held, shareholders will receive an additional share. The ex-date for this bonus issue is September 8, 2025, which is also the record date. This is the latest information regarding their bonus history. If you have any more questions about Hamps Bio or need further details, feel free to ask!

What is the technical trend for Hamps Bio?

As of May 29, 2025, Hamps Bio's technical trend is mildly bearish, indicated by the Dow Theory and a lack of bullish signals in the MACD, with the price near its 52-week low and a year-to-date decline of 50.65%.

As of 29 May 2025, the technical trend for Hamps Bio has changed from sideways to mildly bearish. The weekly Dow Theory indicates a mildly bearish stance, and the MACD shows no signal on the weekly and monthly charts. The Bollinger Bands are sideways on the weekly timeframe, suggesting a lack of volatility. The current price is near the lower end of its 52-week range, with a significant decline of 50.65% year-to-date compared to a positive return from the Sensex. Overall, the technical stance is mildly bearish, driven primarily by the Dow Theory and the lack of bullish signals in the MACD.

Who are the top shareholders of the Hamps Bio?

The top shareholders of Hamps Bio are mainly promoters, with Herrik Mountbaton Shah holding the largest share at 31.12%. Individual investors own 24.66% of the shares, while there are no holdings from mutual funds or foreign institutional investors.

The top shareholders of Hamps Bio are primarily the promoters, with Herrik Mountbaton Shah being the individual with the highest holding at 31.12%. Additionally, individual investors collectively hold 24.66% of the company's shares. There are currently no holdings from mutual funds or foreign institutional investors.

Has Hamps Bio declared dividend?

No Dividend History Available